Cargando…
Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
PURPOSE: Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations. PATIENTS AND METHODS: This multicenter, prospective cohort study enrolled parti...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260917/ https://www.ncbi.nlm.nih.gov/pubmed/34322651 http://dx.doi.org/10.1200/PO.18.00217 |
_version_ | 1783718904463360000 |
---|---|
author | Idos, Gregory E. Kurian, Allison W. Ricker, Charité Sturgeon, Duveen Culver, Julie O. Kingham, Kerry E. Koff, Rachel Chun, Nicolette M. Rowe-Teeter, Courtney Lebensohn, Alexandra P. Levonian, Peter Lowstuter, Katrina Partynski, Katlyn Hong, Christine Mills, Meredith A. Petrovchich, Iva Ma, Cindy S. Hartman, Anne-Renee Allen, Brian Wenstrup, Richard J. Lancaster, Johnathan M. Brown, Krystal Kidd, John Evans, Brent Mukherjee, Bhramar McDonnell, Kevin J. Ladabaum, Uri Ford, James M. Gruber, Stephen B. |
author_facet | Idos, Gregory E. Kurian, Allison W. Ricker, Charité Sturgeon, Duveen Culver, Julie O. Kingham, Kerry E. Koff, Rachel Chun, Nicolette M. Rowe-Teeter, Courtney Lebensohn, Alexandra P. Levonian, Peter Lowstuter, Katrina Partynski, Katlyn Hong, Christine Mills, Meredith A. Petrovchich, Iva Ma, Cindy S. Hartman, Anne-Renee Allen, Brian Wenstrup, Richard J. Lancaster, Johnathan M. Brown, Krystal Kidd, John Evans, Brent Mukherjee, Bhramar McDonnell, Kevin J. Ladabaum, Uri Ford, James M. Gruber, Stephen B. |
author_sort | Idos, Gregory E. |
collection | PubMed |
description | PURPOSE: Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations. PATIENTS AND METHODS: This multicenter, prospective cohort study enrolled participants from three cancer genetics clinics—University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer Institute—who met testing guidelines or had a 2.5% or greater probability of a pathogenic variant (N = 2,000). All patients underwent 25- or 28-gene MGPT and results were compared with differential genetic diagnoses generated by pretest expert clinical assessment. Post-test surveys on distress, uncertainty, and positive experiences were administered at 3 months (69% response rate) and 1 year (57% response rate). RESULTS: Of 2,000 participants, 81% were female, 41% were Hispanic, 26% were Spanish speaking only, and 30% completed high school or less education. A total of 242 participants (12%) carried one or more pathogenic variant (positive), 689 (34%) carried one or more variant of uncertain significance (VUS), and 1,069 (53%) carried no pathogenic variants or VUS (negative). More than one third of pathogenic variants (34%) were not included in the differential diagnosis. After testing, few patients (4%) had prophylactic surgery, most (92%) never regretted testing, and most (80%) wanted to know all results, even those of uncertain significance. Positive patients were twice as likely as negative/VUS patients (83% v 41%; P < .001) to encourage their relatives to be tested. CONCLUSION: In a racially/ethnically and socioeconomically diverse cohort, MGPT increased diagnostic yield. More than one third of identified pathogenic variants were not clinically anticipated. Patient regret and prophylactic surgery use were low, and patients appropriately encouraged relatives to be tested for clinically relevant results. |
format | Online Article Text |
id | pubmed-8260917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-82609172021-07-27 Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk Idos, Gregory E. Kurian, Allison W. Ricker, Charité Sturgeon, Duveen Culver, Julie O. Kingham, Kerry E. Koff, Rachel Chun, Nicolette M. Rowe-Teeter, Courtney Lebensohn, Alexandra P. Levonian, Peter Lowstuter, Katrina Partynski, Katlyn Hong, Christine Mills, Meredith A. Petrovchich, Iva Ma, Cindy S. Hartman, Anne-Renee Allen, Brian Wenstrup, Richard J. Lancaster, Johnathan M. Brown, Krystal Kidd, John Evans, Brent Mukherjee, Bhramar McDonnell, Kevin J. Ladabaum, Uri Ford, James M. Gruber, Stephen B. JCO Precis Oncol Original Report PURPOSE: Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations. PATIENTS AND METHODS: This multicenter, prospective cohort study enrolled participants from three cancer genetics clinics—University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer Institute—who met testing guidelines or had a 2.5% or greater probability of a pathogenic variant (N = 2,000). All patients underwent 25- or 28-gene MGPT and results were compared with differential genetic diagnoses generated by pretest expert clinical assessment. Post-test surveys on distress, uncertainty, and positive experiences were administered at 3 months (69% response rate) and 1 year (57% response rate). RESULTS: Of 2,000 participants, 81% were female, 41% were Hispanic, 26% were Spanish speaking only, and 30% completed high school or less education. A total of 242 participants (12%) carried one or more pathogenic variant (positive), 689 (34%) carried one or more variant of uncertain significance (VUS), and 1,069 (53%) carried no pathogenic variants or VUS (negative). More than one third of pathogenic variants (34%) were not included in the differential diagnosis. After testing, few patients (4%) had prophylactic surgery, most (92%) never regretted testing, and most (80%) wanted to know all results, even those of uncertain significance. Positive patients were twice as likely as negative/VUS patients (83% v 41%; P < .001) to encourage their relatives to be tested. CONCLUSION: In a racially/ethnically and socioeconomically diverse cohort, MGPT increased diagnostic yield. More than one third of identified pathogenic variants were not clinically anticipated. Patient regret and prophylactic surgery use were low, and patients appropriately encouraged relatives to be tested for clinically relevant results. American Society of Clinical Oncology 2019-03-28 /pmc/articles/PMC8260917/ /pubmed/34322651 http://dx.doi.org/10.1200/PO.18.00217 Text en © 2018 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Report Idos, Gregory E. Kurian, Allison W. Ricker, Charité Sturgeon, Duveen Culver, Julie O. Kingham, Kerry E. Koff, Rachel Chun, Nicolette M. Rowe-Teeter, Courtney Lebensohn, Alexandra P. Levonian, Peter Lowstuter, Katrina Partynski, Katlyn Hong, Christine Mills, Meredith A. Petrovchich, Iva Ma, Cindy S. Hartman, Anne-Renee Allen, Brian Wenstrup, Richard J. Lancaster, Johnathan M. Brown, Krystal Kidd, John Evans, Brent Mukherjee, Bhramar McDonnell, Kevin J. Ladabaum, Uri Ford, James M. Gruber, Stephen B. Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk |
title | Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk |
title_full | Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk |
title_fullStr | Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk |
title_full_unstemmed | Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk |
title_short | Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk |
title_sort | multicenter prospective cohort study of the diagnostic yield and patient experience of multiplex gene panel testing for hereditary cancer risk |
topic | Original Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260917/ https://www.ncbi.nlm.nih.gov/pubmed/34322651 http://dx.doi.org/10.1200/PO.18.00217 |
work_keys_str_mv | AT idosgregorye multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT kurianallisonw multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT rickercharite multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT sturgeonduveen multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT culverjulieo multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT kinghamkerrye multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT koffrachel multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT chunnicolettem multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT roweteetercourtney multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT lebensohnalexandrap multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT levonianpeter multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT lowstuterkatrina multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT partynskikatlyn multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT hongchristine multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT millsmereditha multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT petrovchichiva multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT macindys multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT hartmanannerenee multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT allenbrian multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT wenstruprichardj multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT lancasterjohnathanm multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT brownkrystal multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT kiddjohn multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT evansbrent multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT mukherjeebhramar multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT mcdonnellkevinj multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT ladabaumuri multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT fordjamesm multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk AT gruberstephenb multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk |